Phase 3 Recruiting Academic/Other
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal a…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Connecticut: - Smilow Cancer Hospital Care Center at Saint Francis — Hartford, Connecticut
- Smilow Cancer Center/Yale-New Haven Hospital — New Haven, Connecticut
- Yale University — New Haven, Connecticut
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Connecticut: - Eastern CT Hematology & Oncology Associates ( Site 0033) — Norwich, Connecticut
Phase 3 Recruiting Industry
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…
Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Connecticut: - Yale University (Adults and Pediatrics) — New Haven, Connecticut
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…
Sponsor: BeOne Medicines
NCT ID: NCT06742996
Sites in Connecticut: - Yale University Yale Cancer Center — New Haven, Connecticut
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Connecticut: - Norwalk Medical Group — Norwalk, Connecticut
Phase 3 Recruiting Industry
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+),…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06784752
Sites in Connecticut: - Hartford Hospital — Hartford, Connecticut
- Yale New Haven Hospital — New Haven, Connecticut
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Connecticut: - Connecticut Children's Medical Center — Hartford, Connecticut
Phase 2 Recruiting Network
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (ref…
Sponsor: Children's Oncology Group
NCT ID: NCT02981628
Sites in Connecticut: - Connecticut Children's Medical Center — Hartford, Connecticut
- Yale University — New Haven, Connecticut
Phase 2 Recruiting NIH
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in Connecticut: - Connecticut Children's Medical Center — Hartford, Connecticut
- Yale University — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory…
Sponsor: Curis, Inc.
NCT ID: NCT03328078
Sites in Connecticut: - Smilow Cancer Hospital at Yale-New Haven — New Haven, Connecticut
Phase 2 Recruiting Academic/Other
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hemato…
Sponsor: Pediatric Transplantation & Cellular Therapy Consortium
NCT ID: NCT03509961
Sites in Connecticut: - Yale University School of Medicine — New Haven, Connecticut
Phase 2 Recruiting Industry
The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for st…
Sponsor: AstraZeneca
NCT ID: NCT05952024
Sites in Connecticut: - Research Site — Stamford, Connecticut
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…
Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in Connecticut: - Hartford Hospital (site 210) — Hartford, Connecticut
Phase 2 Recruiting Academic/Other
BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA)…
Sponsor: Brown University
NCT ID: NCT04792502
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 2 Recruiting Academic/Other
Single-arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) or CHOEP in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T-cell…
Sponsor: Yale University
NCT ID: NCT05996185
Sites in Connecticut: - Yale Cancer Center, Clinical Trials Office — New Haven, Connecticut
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) a…
Sponsor: Pfizer
NCT ID: NCT03460977
Sites in Connecticut: - Norwalk Hospital — Norwalk, Connecticut
Phase 1 Recruiting Industry
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
Sponsor: Nurix Therapeutics, Inc.
NCT ID: NCT05131022
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclona…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05272384
Sites in Connecticut: - Yale University — New Haven, Connecticut
Phase 1 Recruiting Industry
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be …
Sponsor: Arvinas Inc.
NCT ID: NCT06393738
Sites in Connecticut: - Clinical Trial Site — New Haven, Connecticut
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Connecticut: - Veterans Affairs Connecticut Healthcare System-West Haven Campus — West Haven, Connecticut
Recruiting Network
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in Connecticut: - Yale New Haven Hospital — New Haven, Connecticut
Recruiting Network
This study assesses how blood cell growth patterns (clonal hematopoiesis) relate to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead …
Sponsor: Children's Oncology Group
NCT ID: NCT05705531
Sites in Connecticut: - Connecticut Children's Medical Center — Hartford, Connecticut
- Yale University — New Haven, Connecticut